← Patent-cliff monitor Loss of exclusivity November 2036 latest FDA-listed patent expiry
Drug detail Brand name BIKTARVY Active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE Strength EQ 50MG BASE;200MG;EQ 25MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2018 Marketing status RX
Listed patents Patent Expires Type 12594244 November 2036 product 11744802 November 2036 product 10548846 November 2036 product 9708342 June 2035 substance, product 10385067 June 2035 use U-257 9216996 December 2033 substance, product 9732092 December 2033 substance, product 8754065*PED February 2033 — 9296769*PED February 2033 — 9296769 August 2032 substance, product 8754065 August 2032 substance, product
Regulatory exclusivity Code Expires ODE-540 July 2032 ODE-468 February 2031 M-305 April 2027 I-942 February 2027 ODE-256 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.